ArticleCurrent HIV research2026
Metastasis-Specific Biomarker SPP1 and its Characterization in Colorectal Cancer with HIV Infection.
Article in Current HIV research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSecreted phosphoprotein 1 (SPP1) is upregulated in cancers, but its role in metastatic colorectal cancer (CRC) and expression in HIV-associated CRC remain unclear.
methodsTranscriptomic data from the GEO and TCGA databases were analyzed. Metastasisspecific genes were identified. SPP1-associated functions were explored using GO enrichment, KEGG pathway analysis, and GSVA. Prognostic value was assessed. SPP1 expression was evaluated in 30 CRC specimens (15 HIV-positive, 15 HIV-negative) via immunohistochemistry.
resultsSPP1 exhibited a metastasis-specific expression pattern. High SPP1 correlated with significantly elevated immune cell infiltration and adverse clinicopathological features: older age, mucinous adenocarcinoma, lymphatic invasion, advanced stage, high TN stage, MSI-H status, absence of polyps, and poor prognosis. GO enrichment linked SPP1 to extracellular matrix organization, cell adhesion, immune response, inflammation, and receptor binding. KEGG analysis showed enrichment in HIV-1 infection pathways. However, overall SPP1 expression did not significantly differ between HIV-positive and HIV-negative CRC tissues. Diffuse SPP1 protein expression was noted in an HIV-positive signet-ring cell carcinoma. DISCUSSION: SPP1 is a pivotal driver of CRC metastasis and immune regulation in the tumor microenvironment, and is associated with aggressive disease and poor outcomes. It shows strong potential as a prognostic biomarker. While HIV status did not broadly alter SPP1 expression, its specific pattern in certain HIV-associated carcinomas requires further study.
conclusionSPP1 critically mediates metastasis and immune regulation in CRC and independently predicts poor survival. Its prognostic value is confirmed, warranting investigation into its role in specific HIV-related carcinomas.
Indexed as
Identifiers
41879440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.